Estimation of the Prevalence of HER2 low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice among Unresectable and/or Metastatic Breast Cancer Patients with HER2 low Status

Trial Identifier: D9673R00004
Sponsor: AstraZeneca
Daiichi Sankyo
NCTID:: NCT04807595
Start Date: May 2021
Primary Completion Date: April 2022
Study Completion Date: April 2022
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Australia Melbourne, Australia
Canada, QC Montreal, QC, Canada, H3T 1R2
France Clermont-Ferrand, France, 63011
Germany Erlangen, Germany, 91054
Italy Milano, Italy, 20141
Japan Chuo-ku, Japan, 104-8560
Japan Fukuoka, Japan, 811-1395
Japan Isehara, Japan, 259-1193
Portugal Lisbon, Portugal, 1649-035
Portugal Porto, Portugal, 4200-319
South Korea Seoul, South Korea, 03722
UK Manchester, UK, M20 4BX
USA, PA Pittsburgh, PA, USA, 15213